Mallika Dhawan

MD

Medical oncologist
Medical Director, Cancer Risk and Hereditary Cancers

About me

Dr. Mallika Dhawan is an oncologist whose focus is medical treatments for cancer, such as chemotherapy. She specializes in caring for patients with hereditary cancer syndromes.

Dhawan designs clinical trials – studies to evaluate promising new treatments – and cares for patients with advanced cancers who are seeking such experimental therapies. In addition to her research to discover and develop drugs for patients with advanced cancers, she studies cancer prevention for patients with mutations that raise their risk for hereditary cancers.

Dhawan earned her bachelor's degree in engineering as well as her medical degree at the University of California, San Diego. She completed a residency in internal medicine at Duke University, followed by an oncology fellowship at UCSF. She subsequently completed additional training in cancer genetics.

  • Education

    UC San Diego School of Medicine, 2011

    UC San Diego, BS, Engineering, 2006

  • Residencies

    Duke University Medical Center, Internal Medicine, 2011

  • Fellowships

    UCSF, Oncology, 2017

  • Academic Title

    Assistant Professor

Hereditary Cancer Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Cancer Genetics and Prevention Program

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

My reviews

4.9

Overall Experience
67 Reviews
I have a condition where I see a lot of physicians. I can easily say that no doctor has spent as much time or has had more consideration and empathy as Dr Dhawan. Her recommendations have made more of a difference in quality of my life than any other doctor. I couldn't be happier with her level of care. Love her!!
Explained things in a way that was easy to understand
65 Reviews
Did the doctor pay attention to your concerns
67 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
66 Reviews
Knew the important information about your medical history
67 Reviews
The provider showed respect for what you had to say
67 Reviews
The provider spent enough time with me
66 Reviews
Decorative Caduceus

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK ...

Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

Recruiting

Decorative Caduceus

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous R...

ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed...

Recruiting

Share